LGNDHealthcare · BiotechnologyThe 11 Wall Street analysts covering Ligand Pharmaceuticals, Inc. hold a median 12-month price target of $345 — +13.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 24 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Ligand Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LGND, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.7% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Barclays | Initiates | Overweight | $345 |
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $358 |
| 23 Sept 2026 | Citigroup | Maintains | Buy | $390 → $397 |
| 14 Aug 2026 | Leerink Partners | Initiates | Outperform | $330 |
| 14 Aug 2026 | Leerink Partners | Initiates | Outperform | — |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $340 → $345 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $289 → $358 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Aug 2026 | Oppenheimer | Reiterates | Outperform | — |
| 3 Aug 2026 | Oppenheimer | Reiterates | Outperform | $285 → $326 |
| 21 July 2026 | Citigroup | Reinstates | Buy | $387 |
| 15 July 2026 | RBC Capital | Maintains | Outperform | — |
| 15 July 2026 | RBC Capital | Maintains | Outperform | $262 → $340 |
| 9 July 2026 | B of A Securities | Maintains | Buy | — |
| 9 July 2026 | B of A Securities | Maintains | Buy | $266 → $388 |
| 8 July 2026 | Stifel | Maintains | Buy | — |
| 8 July 2026 | Stifel | Maintains | Buy | $255 → $332 |
| 8 May 2026 | RBC Capital | Maintains | Outperform | — |
| 30 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LGND appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Ligand Pharmaceuticals, Inc. returned +63.8% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 8% of US stocks
Cheaper than 15% of US stocks
Cheaper than 5% of US stocks
Higher than 80% of US stocks
Higher than 97% of US stocks
Higher than 98% of US stocks
Higher than 70% of US stocks
Higher than 98% of US stocks
Higher than 83% of US stocks
Higher than 71% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ligand Pharmaceuticals, Inc. has a market value of $6.1B and an enterprise value of $5.8B.
Revenue in the twelve months to 30 June 2026: $290.5M. The latest quarter grew 33.7% year on year.
Net income over the same four quarters: $197.2M, a 67.9% net margin.
Diluted earnings per share, trailing twelve months: $9.35.
Free cash flow in the twelve months to 30 June 2026: $119.8M.
Trailing P/E: 32.0×; forward P/E: 25.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ligand Pharmaceuticals, Inc. employs 47 people — $6.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ligand Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ligand Pharmaceuticals announced that it will host an Investor Day on December 8, 2026.
Why it matters — LGND watchers may note the scheduled event as an opportunity to hear information from the company.
Ligand Pharmaceuticals announced that it will report its third-quarter 2026 financial results on Thursday, October 29, 2026.
Why it matters — LGND watchers may note the scheduled date for the company’s third-quarter results.
Ligand Pharmaceuticals announced a financing agreement with AvenCell Therapeutics, a clinical-stage cell therapy company developing allogeneic CAR-T therapies for cancer, for up to $47 million. The agreement is intended to advance AvenCell's pipeline of next-generation CAR-T therapies.
Why it matters — The deal expands Ligand's involvement in the cell therapy space and could generate meaningful financing-related returns as AvenCell's next-generation CAR-T programs advance.
Sydnexis announced a royalty agreement with Ligand Pharmaceuticals in which Ligand will pay $23 million upfront to acquire a 100% interest in certain royalty payments associated with net sales of Ryjunea in Europe, the Middle East, and Africa.
Why it matters — This agreement provides Ligand with a newly acquired royalty interest in EMEA sales of Ryjunea, expanding its portfolio of revenue-generating assets.
Primrose Bio, a provider of production solutions for next-generation biologics, announced the closing of a financing round led by new investor Signet Healthcare Partners, with participation from existing investors including Ligand Pharmaceuticals.
Why it matters — Ligand, as an existing investor in Primrose Bio, participated in this financing round, making the company's capital raise relevant to those following Ligand's investment portfolio.
The 11 Wall Street analysts covering Ligand Pharmaceuticals, Inc. have a median 12-month price target of $345, with estimates ranging from $247 to $406. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Ligand Pharmaceuticals, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ligand Pharmaceuticals, Inc. 71 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Ligand Pharmaceuticals, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +13.7% from the last close, and Ticker Nerd's factor model ranks Ligand Pharmaceuticals, Inc. 71 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ligand Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $247 to $406 over the next 12 months.
Ligand Pharmaceuticals, Inc. returned +63.8% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing technologies and assets that support the discovery and development of medicines. Ligand Pharmaceuticals Incorporated operates a royalty-driven business model, partnering with other biopharmaceutical companies to finance and advance late-stage clinical programs while also managing a broad portfolio of royalty interests.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Ligand to Host Investor Day on December 8, 2026". Ligand Pharmaceuticals announced that it will host an Investor Day on December 8, 2026.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing technologies and assets that support the discovery and development of medicines. Ligand Pharmaceuticals Incorporated operates a royalty-driven business model, partnering with other biopharmaceutical companies to finance and advance late-stage clinical programs while also managing a broad portfolio of royalty interests. Its current portfolio spans commercial, clinical, and preclinical-stage assets across multiple therapeutic areas, including infectious diseases, oncology, respiratory conditions, kidney disease, and rare diseases. The company also works through technology licensing and asset acquisition activities to expand the range of medicines connected to its platform. Based in Jupiter, Florida, Ligand Pharmaceuticals Incorporated plays a specialized role in the life sciences market by providing capital, expertise, and royalty management across a diversified set of partnered drug programs.
CEO Mr. Todd C. Davis Ph.D. · 47 employees · United States · https://www.ligand.com
